Log in

NYSE:IMV - IMV Stock Price, Forecast & News

$2.98
+0.16 (+5.67 %)
(As of 12/11/2019 01:29 AM ET)
Today's Range
$2.75
Now: $2.98
$2.98
50-Day Range
$2.30
MA: $2.64
$3.06
52-Week Range
$2.11
Now: $2.98
$5.95
Volume42,856 shs
Average Volume19,242 shs
Market Capitalization$150.88 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
IMV, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm's patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorHealth Technology
CUSIPN/A
CIKN/A
WebN/A
Phone(902) 492-1819

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$150.88 million
Next Earnings Date3/19/2020 (Estimated)
OptionableNot Optionable

Receive IMV News and Ratings via Email

Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter.


IMV (NYSE:IMV) Frequently Asked Questions

What is IMV's stock symbol?

IMV trades on the New York Stock Exchange (NYSE) under the ticker symbol "IMV."

How were IMV's earnings last quarter?

Imv Inc (NYSE:IMV) released its earnings results on Friday, November, 8th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.03. The company earned $0.12 million during the quarter, compared to analyst estimates of $0.05 million. View IMV's Earnings History.

When is IMV's next earnings date?

IMV is scheduled to release their next quarterly earnings announcement on Thursday, March 19th 2020. View Earnings Estimates for IMV.

What price target have analysts set for IMV?

6 brokerages have issued 1 year price targets for IMV's shares. Their forecasts range from $10.00 to $12.25. On average, they anticipate IMV's stock price to reach $11.19 in the next twelve months. This suggests a possible upside of 275.4% from the stock's current price. View Analyst Price Targets for IMV.

What is the consensus analysts' recommendation for IMV?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMV in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IMV.

What are Wall Street analysts saying about IMV stock?

Here are some recent quotes from research analysts about IMV stock:
  • 1. According to Zacks Investment Research, "IMV Inc. is a clinical-stage immuno-oncology company. Its proprietary drug development platform provides a patented delivery formulation which enables controlled and prolonged exposure of antigens to the immune system. The company's pipeline consists of DPX-Survivac, DPX-E7 and DPX-RSV which are in clinical stage. IMV Inc. is based in Halifax, Canada. " (11/13/2019)
  • 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $11.50 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our valuation is currently based on the opportunities in the U.S. for only DPX-Survivac, the leading asset, in ovarian cancer (approximately 43% valuation contribution, 30% chance of success), DLBCL (15% valuation contribution, 15% chance of success), and the indications in the basket trial (41% valuation contribution, 10% chance of success)." (6/12/2019)

Has IMV been receiving favorable news coverage?

News coverage about IMV stock has trended very negative this week, according to InfoTrie. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. IMV earned a daily sentiment score of -3.9 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for IMV.

Who are some of IMV's key competitors?

What other stocks do shareholders of IMV own?

Who are IMV's key executives?

IMV's management team includes the folowing people:
  • Frederic Ors, CEO, Director & Chief Business Officer
  • Pierre Labbé, Chief Financial Officer
  • Gabriela Nicola Rosu, Chief Medical Officer
  • Marianne Stanford, Vice President-Research
  • Joseph Sullivan, Senior Vice President-Business Development

Who are IMV's major shareholders?

IMV's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Hartford Financial Management Inc. (0.08%).

Which institutional investors are buying IMV stock?

IMV stock was purchased by a variety of institutional investors in the last quarter, including Hartford Financial Management Inc..

How do I buy shares of IMV?

Shares of IMV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is IMV's stock price today?

One share of IMV stock can currently be purchased for approximately $2.98.

How big of a company is IMV?

IMV has a market capitalization of $150.88 million. View Additional Information About IMV.

How can I contact IMV?

The company can be reached via phone at (902) 492-1819.


MarketBeat Community Rating for IMV (NYSE IMV)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  82 (Vote Outperform)
Underperform Votes:  77 (Vote Underperform)
Total Votes:  159
MarketBeat's community ratings are surveys of what our community members think about IMV and other stocks. Vote "Outperform" if you believe IMV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel